‘Third Sector’ Drug Sales Will Grow To $14 Billion In U.S. In 2018 – IMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Products based on older ingredients but offering new routes of administration, new formulations or new indications should continue to see solid growth, IMS white paper says; leading players in the space include both brand and generic firms.
You may also be interested in...
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Rebate Proposals Targeting Single-Use Vials May Be Barking Up The Wrong Tree
Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: